Why Doctors Don’t Recommend Upatinib/Ref for All Patients

Upadacitinib is a Janus kinase (JAK) inhibitor commonly used to treat a variety of immune diseases, such as rheumatoid arthritis (RA), psoriatic arthritis, ulcerative colitis, etc. Although the drug has significant therapeutic benefits for many patients, not all patients are candidates for upadacitinib. When doctors decide whether to use upadatinib, they usually consider comprehensive factors such as the patient's health status, disease type, drug interactions, etc.

First, upadatinib may not be suitable for patients with severe immune system problems. As an immunosuppressant, upadacitinib slows down the inflammatory process by interfering with the immune response, which means it may increase the risk of infection. In immunocompromised patients (such as those following immunosuppressive therapy or those with immunodeficiencies), use of upadacitinib may result in an increased risk of bacterial, viral, or fungal infections, and may even cause some common infections to become more severe. Therefore, doctors usually carefully assess the patient's immune status and avoid prescribing this drug to patients with severe immune dysfunction.

Second, upadatinib may have adverse effects in patients with hepatic insufficiency. The metabolism of JAK inhibitors mainly depends on the liver. If the patient has liver disease or impaired liver function, the use of such drugs may cause the drugs to accumulate in the body, causing toxic reactions. In this case, the doctor will decide whether to use upadacitinib based on the patient's liver function status, and may adjust the dose or choose other treatment options.

For some patients who are already taking other immunosuppressants (such as biological agents, otherJAK inhibitors, etc.), doctors will also avoid the use of upadatinib. The combined use of multiple immunosuppressants may potentiate the immunosuppressive effects of the drugs and increase the risk of infection, leukemia, and other serious complications. Therefore, upadatinib is not recommended for use in combination with other JAK inhibitors or strong immunosuppressants unless carefully evaluated by a physician.

Reference materials:https://www.rinvoq.com/